This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.
This report provides analyses of products, markets, and competitors in the global market for osteoporosis diagnostic products. This market, as covered by the scope of this report, includes products that are used to diagnose osteoporosis, including bone densitometry systems and bone remodeling biochemical marker tests.
The Asia-Pacific (APAC) region is a part of the world which includes several developing and developed countries. Countries covered in this report include Australia, China, India, Japan, Malaysia, South Korea, Thailand, and Vietnam.
In this report, we cover catalysts from 35 drugs, devices, diagnostics, and deals expected to occur in Q4 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.
In 2015, the global point-of-care (POC) clinical diagnostic products market was valued at $14.7bn, comprising 28% of the total in vitro diagnostics (IVD) market.
This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and interventional procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
This report provides a summary of the nearly $2 billion U.S. patient monitoring devices market.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!